Search Results - "Neff, Thomas B"

Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study by Provenzano, Robert, MD, Besarab, Anatole, MD, Wright, Steven, MD, Dua, Sohan, MD, Zeig, Steven, MD, Nguyen, Peter, MD, Poole, Lona, MD, Saikali, Khalil G., PhD, Exec MBA, Saha, Gopal, MBBS, Hemmerich, Stefan, PhD, RAC, Szczech, Lynda, MD, MSCE, Yu, K.H. Peony, MD, Neff, Thomas B., MD (hc)

“…Background Roxadustat (FG-4592) is an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor that promotes erythropoiesis through increasing endogenous…”
Get full text

Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients by Besarab, Anatole, Provenzano, Robert, Hertel, Joachim, Zabaneh, Raja, Klaus, Stephen J, Lee, Tyson, Leong, Robert, Hemmerich, Stefan, Yu, Kin-Hung Peony, Neff, Thomas B

“…Roxadustat (FG-4592) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis. This Phase 2a study tested efficacy (Hb…”
Get full text

Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China by Chen, Nan, Qian, Jiaqi, Chen, Jianghua, Yu, Xueqing, Mei, Changlin, Hao, Chuanming, Jiang, Gengru, Lin, Hongli, Zhang, Xinzhou, Zuo, Li, He, Qiang, Fu, Ping, Li, Xuemei, Ni, Dalvin, Hemmerich, Stefan, Liu, Cameron, Szczech, Lynda, Besarab, Anatole, Neff, Thomas B, Peony Yu, Kin-Hung, Valone, Frank H

“…FG-4592 (roxadustat) is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (HIF-PHI) promoting coordinated erythropoiesis through the…”
Get full text

Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease by Del Balzo, Ughetta, Signore, Pierre E, Walkinshaw, Gail, Seeley, Todd W, Brenner, Mitchell C, Wang, Qingjian, Guo, Guangjie, Arend, Michael P, Flippin, Lee A, Chow, F Aisha, Gervasi, David C, Kjaergaard, Christian H, Langsetmo, Ingrid, Guenzler, Volkmar, Liu, David Y, Klaus, Steve J, Lin, Al, Neff, Thomas B

“…Anemia of chronic kidney disease (CKD) is a multifactorial disorder caused by impaired erythropoietin (EPO) production and altered iron homeostasis associated…”
Get full text

Oral Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG‐4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo‐Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients by Provenzano, Robert, Tumlin, James, Zabaneh, Raja, Chou, James, Hemmerich, Stefan, Neff, Thomas B., Yu, K.‐H. Peony

“…Roxadustat (FG‐4592), an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis, was evaluated in a phase 1b study in…”
Get full text

Phase 1 Study of Anti-CTGF Monoclonal Antibody in Patients with Diabetes and Microalbuminuria by Adler, Sharon G., Schwartz, Sherwyn, Williams, Mark E., Arauz-Pacheco, Carlos, Bolton, Warren K., Lee, Tyson, Li, Dongxia, Neff, Thomas B., Urquilla, Pedro R., Sewell, K. Lea

“…This report summarizes the first phase 1 trial treating patients with microalbuminuric diabetic kidney disease (DKD) using FG-3019, a human monoclonal antibody…”
Get full text

Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer by Seeley, Todd W, Sternlicht, Mark D, Klaus, Stephen J, Neff, Thomas B, Liu, David Y

“…The effects of pharmacological hypoxia-inducible factor (HIF) stabilization were investigated in the MMTV-Neu -YD5 (NeuYD) mouse model of breast cancer. This…”
Get full text

Retraction notice to “Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis.” Kidney Int Rep. 2021;6:613–623 by Provenzano, Robert, Fishbane, Steven, Szczech, Lynda, Leong, Robert, Saikali, Khalil G., Zhong, Ming, Lee, Tyson T., Houser, Mark T., Frison, Lars, Houghton, John, Little, Dustin J., Peony Yu, Kin-Hung, Neff, Thomas B.

“…[This retracts the article DOI: 10.1016/j.ekir.2020.12.018.]…”
Get full text

Roxadustat for anemia in patients with end-stage renal disease incident to dialysis by Provenzano, Robert, Shutov, Evgeny, Eremeeva, Liubov, Korneyeva, Svitlana, Poole, Lona, Saha, Gopal, Bradley, Charles, Eyassu, Meraf, Besarab, Anatole, Leong, Robert, Liu, Cameron S, Neff, Thomas B, Szczech, Lynda, Yu, Kin-Hung P

“…Abstract Background We evaluated the efficacy and safety of roxadustat versus epoetin alfa for the treatment of chronic kidney disease-related anemia in…”
Get full text

Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients by Besarab, Anatole, Chernyavskaya, Elena, Motylev, Igor, Shutov, Evgeny, Kumbar, Lalathaksha M, Gurevich, Konstantin, Chan, Daniel Tak Mao, Leong, Robert, Poole, Lona, Zhong, Ming, Saikali, Khalil G, Franco, Marietta, Hemmerich, Stefan, Yu, Kin-Hung Peony, Neff, Thomas B

“…Safety concerns with erythropoietin analogues and intravenous (IV) iron for treatment of anemia in CKD necessitate development of safer therapies. Roxadustat…”
Get full text

Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD by Provenzano, Robert, Besarab, Anatole, Sun, Chao H, Diamond, Susan A, Durham, John H, Cangiano, Jose L, Aiello, Joseph R, Novak, James E, Lee, Tyson, Leong, Robert, Roberts, Brian K, Saikali, Khalil G, Hemmerich, Stefan, Szczech, Lynda A, Yu, Kin-Hung Peony, Neff, Thomas B

“…Roxadustat (FG-4592), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis, regulates iron metabolism, and reduces…”
Get full text

Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials by Provenzano, Robert, Szczech, Lynda, Leong, Robert, Saikali, Khalil G, Zhong, Ming, Lee, Tyson T, Little, Dustin J, Houser, Mark T, Frison, Lars, Houghton, John, Neff, Thomas B

“…We evaluated the efficacy and cardiovascular safety of roxadustat versus placebo by analyzing data pooled from three phase 3 studies of roxadustat in patients…”
Get full text

Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis by Provenzano, Robert, Fishbane, Steven, Szczech, Lynda, Leong, Robert, Saikali, Khalil G, Zhong, Ming, Lee, Tyson T, Houser, Mark T, Frison, Lars, Houghton, John, Little, Dustin J, Peony Yu, Kin-Hung, Neff, Thomas B

“…Erythropoiesis-stimulating agents are associated with increased cardiovascular risk when higher doses are used toward higher hematocrit targets. Patients new…”
Get full text

Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ± pamrevlumab (P) as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC) by Picozzi, Vincent J., Rocha, Flavio G., Helton, Scott, Pishvaian, Michael J., Jackson, Patrick G, Mody, Kabir, Asbun, Horacio, Carney, Mairead, Etheridge, Tina, Neff, Thomas B, Porter, Seth, Zhong, Ming, Valone, Frank, Kouchakji, Elias, Imperial, Joanne C., Carrier, Ewa

“…Abstract only 365 Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by dense stroma and connective tissue growth factor (CTGF)…”
Get full text

Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ±FG-3019 as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC) by Picozzi, Vincent J., Rocha, Flavio G., Helton, Scott, Mody, Kabir, Asbun, Horacio, Pishvaian, Michael J., Jackson, Patrick G, Etheridge, Tina, Carney, Mairead, Neff, Thomas B, Porter, Seth, Crans, Gerald, Valone, Frank, Shi, Wen

“…Abstract only 457 Background: Curative therapy for PDAC is currently achievable through resection only, but ≤ 15% of patients are candidates for surgery…”
Get full text

RETRACTED: Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis by Provenzano, Robert, Fishbane, Steven, Szczech, Lynda, Leong, Robert, Saikali, Khalil G., Zhong, Ming, Lee, Tyson T., Houser, Mark T., Frison, Lars, Houghton, John, Little, Dustin J., Peony Yu, Kin-Hung, Neff, Thomas B.

“…This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). There were significant…”
Get full text